{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T14:58:58Z","timestamp":1783781938947,"version":"3.55.0"},"reference-count":47,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2021,6,29]],"date-time":"2021-06-29T00:00:00Z","timestamp":1624924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Age-related macular degeneration (AMD) is a leading cause of blindness in older adults. One of the strongest genetic risk factors for AMD is a complement factor H (CFH) gene polymorphism characterized by a tyrosine-histidine change at amino acid position 402 (Y402H). The magnitude of this association between the Y402H variant and AMD is among the strongest that has been identified for any complex, multifactorial human disease. This strong association has motivated researchers to investigate a potential link between various elements of the complement pathway and AMD pathogenesis. Given the possible contribution of complement dysregulation to AMD, complement inhibition has emerged as a therapeutic strategy for slowing geographic atrophy (GA). Randomized clinical trials thus far have yielded mixed results. In this article, we provide the historical context for complement inhibition as a strategy for treating GA, discuss potential advantages and disadvantages of complement inhibition, and highlight the questions that must be addressed before complement inhibition can take center stage as a therapy for AMD.<\/jats:p>","DOI":"10.3390\/jcm10132890","type":"journal-article","created":{"date-parts":[[2021,6,29]],"date-time":"2021-06-29T10:52:46Z","timestamp":1624963966000},"page":"2890","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Complement Inhibition for Geographic Atrophy: A Tempting Target with Mixed Results"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2792-7821","authenticated-orcid":false,"given":"Jonathan B.","family":"Lin","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Massachusetts Eye and Ear and Harvard Medical School, Boston, MA 02114, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar A.","family":"Halawa","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Massachusetts Eye and Ear and Harvard Medical School, Boston, MA 02114, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan W.","family":"Miller","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Massachusetts Eye and Ear and Harvard Medical School, Boston, MA 02114, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Demetrios G.","family":"Vavvas","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Massachusetts Eye and Ear and Harvard Medical School, Boston, MA 02114, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,6,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","article-title":"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: A systematic review and meta-analysis","volume":"2","author":"Wong","year":"2014","journal-title":"Lancet Glob. Health"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/eye.2015.48","article-title":"Defining response to anti-VEGF therapies in neovascular AMD","volume":"29","author":"Amoaku","year":"2015","journal-title":"Eye"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Age-Related Eye Disease Study 2 Research Group (2013). Lutein + Zeaxanthin and Omega-3 Fatty Acids for Age-Related Macular Degeneration. JAMA, 309, 2005\u20132015.","DOI":"10.1001\/jama.2013.4997"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1001\/jamaophthalmol.2013.7376","article-title":"Secondary Analyses of the Effects of Lutein\/Zeaxanthin on Age-Related Macular Degeneration Progression: AREDS2 Report No","volume":"132","author":"Chew","year":"2014","journal-title":"JAMA Ophthalmol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1016\/j.ophtha.2013.01.021","article-title":"Long-Term Effects of Vitamins C and E, \u03b2-Carotene, and Zinc on Age-related Macular Degeneration: AREDS Report No","volume":"120","author":"Chew","year":"2013","journal-title":"Ophthalmology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"E696","DOI":"10.1073\/pnas.1718059115","article-title":"CFH and ARMS2 genetic risk determines progression to neovascular age-related macular degeneration after antioxidant and zinc supplementation","volume":"115","author":"Vavvas","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Age-Related Eye Disease Study Research Group (2001). A Randomized, Placebo-Controlled, Clinical Trial of High-Dose Supplementation With Vitamins C and E, Beta Carotene, and Zinc for Age-Related Macular Degeneration and Vision Loss: AREDS Report No. Arch. Ophthalmol., 119, 1417\u20131436.","DOI":"10.1001\/archopht.119.10.1417"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41577-019-0168-x","article-title":"New insights into the immune functions of complement","volume":"19","author":"Reis","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1146\/annurev-immunol-032713-120154","article-title":"Complement and Its Receptors: New Insights into Human Disease","volume":"32","author":"Holers","year":"2014","journal-title":"Annu. Rev. Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1126\/science.1110359","article-title":"Complement Factor H Variant Increases the Risk of Age-Related Macular Degeneration","volume":"308","author":"Haines","year":"2005","journal-title":"Science"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1126\/science.1109557","article-title":"Complement Factor H Polymorphism in Age-Related Macular Degeneration","volume":"308","author":"Klein","year":"2005","journal-title":"Science"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1126\/science.1110189","article-title":"Complement Factor H Polymorphism and Age-Related Macular Degeneration","volume":"308","author":"Edwards","year":"2005","journal-title":"Science"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1167\/iovs.07-1297","article-title":"Functional and Structural Implications of the Complement Factor H Y402H Polymorphism Associated with Age-Related Macular Degeneration","volume":"49","author":"Ormsby","year":"2008","journal-title":"Investig. Opthalmol. Vis. Sci."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1016\/j.molimm.2007.02.012","article-title":"Defective complement control of Factor H (Y402H) and FHL-1 in age-related macular degeneration","volume":"44","author":"Skerka","year":"2007","journal-title":"Mol. Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"8451","DOI":"10.1021\/bi700459a","article-title":"Biochemical Analysis of a Common Human Polymorphism Associated with Age-Related Macular Degeneration","volume":"46","author":"Yu","year":"2007","journal-title":"Biochemistry"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"13757","DOI":"10.1073\/pnas.1121309109","article-title":"Complement factor H genotypes impact risk of age-related macular degeneration by interaction with oxidized phospholipids","volume":"109","author":"Shaw","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/ng.2640","article-title":"A functional variant in the CFI gene confers a high risk of age-related macular degeneration","volume":"45","author":"Nilsson","year":"2013","journal-title":"Nat. Genet."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"The AMD Genetics Clinical Study Group, Gold, B., Merriam, J.E., Zernant, J., Hancox, L.S., Taiber, A.J., Gehrs, K., Cramer, K., Neel, J., and Bergeron, J. (2006). Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration. Nat. Genet., 38, 458\u2013462.","DOI":"10.1038\/ng1750"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"8828","DOI":"10.1167\/iovs.11-7933","article-title":"Complement Factor D in Age-Related Macular Degeneration","volume":"52","author":"Stanton","year":"2011","journal-title":"Investig. Opthalmol. Vis. Sci."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1006\/exer.1999.0798","article-title":"A Potential Role for Immune Complex Pathogenesis in Drusen Formation","volume":"70","author":"Johnson","year":"2000","journal-title":"Exp. Eye Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1006\/exer.2001.1094","article-title":"Complement Activation and Inflammatory Processes in Drusen Formation and Age Related Macular Degeneration","volume":"73","author":"Johnson","year":"2001","journal-title":"Exp. Eye Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S0002-9394(02)01624-0","article-title":"A role for local inflammation in the formation of drusen in the aging eye","volume":"134","author":"Anderson","year":"2002","journal-title":"Am. J. Ophthalmol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1167\/iovs.61.3.18","article-title":"Complement Activation Levels Are Related to Disease Stage in AMD","volume":"61","author":"Heesterbeek","year":"2020","journal-title":"Investig. Opthalmol. Vis. Sci."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.ophtha.2013.09.044","article-title":"Systemic Complement Inhibition with Eculizumab for Geographic Atrophy in Age-Related Macular Degeneration","volume":"121","author":"Yehoshua","year":"2014","journal-title":"Ophthalmology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1001\/jamaophthalmol.2018.1544","article-title":"Efficacy and Safety of Lampalizumab for Geographic Atrophy Due to Age-Related Macular Degeneration: Chroma and Spectri Phase 3 Randomized Clinical Trials","volume":"136","author":"Holz","year":"2018","journal-title":"JAMA Ophthalmol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"eaaf1443","DOI":"10.1126\/scitranslmed.aaf1443","article-title":"Targeting factor D of the alternative complement pathway reduces geographic atrophy progression secondary to age-related macular degeneration","volume":"9","author":"Yaspan","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ophtha.2019.07.011","article-title":"Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration","volume":"127","author":"Liao","year":"2020","journal-title":"Ophthalmology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.ophtha.2020.08.027","article-title":"C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration","volume":"128","author":"Jaffe","year":"2021","journal-title":"Ophthalmology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"6525","DOI":"10.1167\/iovs.14-15067","article-title":"Reliability of the Mouse Model of Choroidal Neovascularization Induced by Laser Photocoagulation","volume":"55","author":"Poor","year":"2014","journal-title":"Investig. Opthalmol. Vis. Sci."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Wykoff, C.C., Rosenfeld, P.J., Waheed, N.K., Singh, R.P., Ronca, N., Slakter, J.S., Staurenghi, G., Mon\u00e9s, J., Baumal, C.R., and Saroj, N. (2021). Characterizing New-Onset Exudation in the Randomized Phase 2 FILLY Trial of Complement Inhibitor Pegcetacoplan for Geographic Atrophy. Ophthalmology.","DOI":"10.1016\/j.ophtha.2021.02.025"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"7684","DOI":"10.1167\/iovs.12-10069","article-title":"A Novel Role of Complement in Retinal Degeneration","volume":"53","author":"Yu","year":"2012","journal-title":"Investig. Opthalmol. Vis. Sci."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.ajpath.2013.04.008","article-title":"Complement Component C3 Plays a Critical Role in Protecting the Aging Retina in a Murine Model of Age-Related Macular Degeneration","volume":"183","author":"Lenassi","year":"2013","journal-title":"Am. J. Pathol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3389\/fnagi.2018.00015","article-title":"The Complement System Is Critical in Maintaining Retinal Integrity during Aging","volume":"10","author":"Mukai","year":"2018","journal-title":"Front. Aging Neurosci."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1084\/jem.20190009","article-title":"C3- and CR3-dependent microglial clearance protects photoreceptors in retinitis pigmentosa","volume":"216","author":"Silverman","year":"2019","journal-title":"J. Exp. Med."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"De Jong, S., Gagliardi, G., Garanto, A., de Breuk, A., Lechanteur, Y.T.E., Katti, S., van den Heuvel, L.P., Volokhina, E.B., and den Hollander, A.I. (2021). Implications of genetic variation in the complement system in age-related macular degeneration. Prog. Retin. Eye Res., 100952.","DOI":"10.1016\/j.preteyeres.2021.100952"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Kim, B.J., Mastellos, D.C., Li, Y., Dunaief, J.L., and Lambris, J.D. (2020). Targeting complement components C3 and C5 for the retina: Key concepts and lingering questions. Prog. Retin. Eye Res., 100936.","DOI":"10.1016\/j.preteyeres.2020.100936"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Scholl, H.P.N., Fleckenstein, M., Fritsche, L.G., Schmitz-Valckenberg, S., G\u00f6bel, A., Adrion, C., Herold, C., Keilhauer, C.N., Mackensen, F., and M\u00f6\u00dfner, A. (2009). CFH, C3 and ARMS2 Are Significant Risk Loci for Susceptibility but Not for Disease Progression of Geographic Atrophy Due to AMD. PLoS ONE, 4.","DOI":"10.1371\/journal.pone.0007418"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1016\/j.ophtha.2009.12.012","article-title":"Progression of Geographic Atrophy and Genotype in Age-Related Macular Degeneration","volume":"117","author":"Klein","year":"2010","journal-title":"Ophthalmology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1001\/jamaophthalmol.2019.1318","article-title":"Assessment of Novel Genome-Wide Significant Gene Loci and Lesion Growth in Geographic Atrophy Secondary to Age-Related Macular Degeneration","volume":"137","author":"Grassmann","year":"2019","journal-title":"JAMA Ophthalmol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Grassmann, F., Fleckenstein, M., Chew, E.Y., Strunz, T., Schmitz-Valckenberg, S., G\u00f6bel, A.P., Klein, M.L., Ratnapriya, R., Swaroop, A., and Holz, F.G. (2015). Clinical and Genetic Factors Associated with Progression of Geographic Atrophy Lesions in Age-Related Macular Degeneration. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0126636"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1016\/j.ophtha.2018.05.028","article-title":"Progression of Geographic Atrophy in Age-related Macular Degeneration: AREDS2 Report Number","volume":"125","author":"Keenan","year":"2018","journal-title":"Ophthalmology"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.ophtha.2012.11.037","article-title":"Pharmacogenetics for Genes Associated with Age-related Macular Degeneration in the Comparison of AMD Treatments Trials (CATT)","volume":"120","author":"Hagstrom","year":"2013","journal-title":"Ophthalmology"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1016\/j.ophtha.2012.05.040","article-title":"Cumulative Effect of Risk Alleles in CFH, ARMS2, and VEGFA on the Response to Ranibizumab Treatment in Age-related Macular Degeneration","volume":"119","author":"Smailhodzic","year":"2012","journal-title":"Ophthalmology"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1089\/ars.2017.7084","article-title":"Oxidative Stress Induces an Interactive Decline in Wnt and Nrf2 Signaling in Degenerating Retinal Pigment Epithelium","volume":"29","author":"Ebrahimi","year":"2018","journal-title":"Antioxid. Redox Signal."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"13094","DOI":"10.1073\/pnas.2000339117","article-title":"Altered photoreceptor metabolism in mouse causes late stage age-related macular degeneration-like pathologies","volume":"117","author":"Cheng","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.preteyeres.2018.06.002","article-title":"NAD+ and sirtuins in retinal degenerative diseases: A look at future therapies","volume":"67","author":"Lin","year":"2018","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.celrep.2016.08.073","article-title":"NAMPT-Mediated NAD+ Biosynthesis Is Essential for Vision In Mice","volume":"17","author":"Lin","year":"2016","journal-title":"Cell Rep."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/13\/2890\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:26:36Z","timestamp":1760163996000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/13\/2890"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,29]]},"references-count":47,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2021,7]]}},"alternative-id":["jcm10132890"],"URL":"https:\/\/doi.org\/10.3390\/jcm10132890","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,29]]}}}